Dr. Jennifer Buell joined the Agenus board in 2024 and has chaired the company's Executive Council since 2023. She has served as President and Chief Executive Officer of MiNK Therapeutics, a publicly traded Agenus affiliate, since 2021, and brings more than 27 years of biopharmaceutical experience advancing programs from discovery through clinical development and commercialization.
From 2018 to 2021 she was President and Chief Operating Officer of Agenus, responsible for operations, investor relations and external affairs, and she has held a range of earlier roles at the company. Prior to Agenus she held R&D operations leadership positions at Bristol-Myers Squibb and the Harvard Clinical Research Institute (now the Baim Institute). She holds a Ph.D. in Cellular, Biochemical and Molecular Biochemistry and an M.S. in Biostatistics from Tufts University.